AKTS
Aktis Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.05
+1.50%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- -$0.45
- Revenue estimate
- $3.8M
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.44
- EPS estimate
- -$0.43
- Revenue actual
- $3.4M
- Revenue estimate
- $2.7M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 0
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -2.2%
- Revenue beats (12Q)
- 1
Analyst ratings
Sell-side consensus
- Consensus
- Strong Buy
- Price target
- $36
- PT range
- $33 – $40
- Analysts
- 4
4 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026